Neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a comparative cohort study

Salido‐Vallejo, Rafael; Cuevas‐Asencio, I.; Garnacho‐Sucedo, G.; González-Menchen, Alberto; Alcántara-Reifs, Carmen María; Corte-Sánchez, Sofía de la; Vélez, Antonio; Moreno‐Giménez, J.C.

doi:10.1111/jdv.13266

Cited by 34 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only One strategy to overcome acquired resistance may be to promote immunogenic cell death by administration cytotoxic agents and/or radiation therapy. However, our attempt to increase immunogenicity by intralesional application of MTX (Salido-Vallejo et al, 2016) failed to re-induce response to treatment in our patient as tumor progressed rapidly without any signs of response.…”

mentioning

confidence: 64%

Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Zalaudek

Corneli

Vernoni

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

mentioning

confidence: 64%

Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Zalaudek

Corneli

Vernoni

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

“…Nevertheless, preliminary data about il-MTX treatment of face KAs is available, even in cases of squamous cell carcinomas as neoadjuvant therapy to surgery. 5 Although we absolutely agree on the surgical approach to a solitary crateriform lesion on the face with no response to il-MTX, we believe that its use can be taken into consideration depending on each individual patient and should not be relegated in all cases when KA arises on the head or neck.…”

mentioning

confidence: 82%

Comment on “Intralesional methotrexate for keratoacanthomas: A retrospective cohort study”

Salido‐Vallejo

Redondo

2020

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: адъювантная системная терапияunclassified

“…Нет достоверных доказательств эффективности адъювантной системной терапии локализованного ПКРК после резекции R0 [128][129][130][131][132][133]. Адъювантная терапия 13-цисретиноевой кислотой и интерфероном не отдаляла возникновение рецидива или новой первичной опухоли [131]. Адъювантная химиотерапия (пероральный прием капецитабина и применение других системных цитотоксических препаратов) или таргетная терапия (ингибиторами EGFR) не входит в общепринятые рекомендации, поскольку отсутствуют доказательства эффективности, основанные на данных о выживаемости [132].…”

Section: адъювантная системная терапияunclassified

Current strategy of squamous cell carcinoma diagnosis and treatment

Поляков

Gevorkov

Степанова

2021

Opuholi golovy i šei

View full text Add to dashboard Cite

Squamous cell carcinoma (SCC) is the second most common skin cancer after basal cell carcinoma. Usually, antitumor treatment is sufficiently effective: recovery rate is about 90 %. Primary SCC is characterized by variable growth rate, as well as by involvement of regional lymph nodes (from 1 % for well differentiated tumors to 10 % for poorly differentiated tumors, size >3 cm and /or invasion depth >4 mm). In case of SCC development near post-burn scar, the rate of regional metastasis is 10-30 %. A relatively small possibility of distant metastasis also exists, with overall mortality of 2-3 %. In SCC of the head and neck, both hematogenic and perineural advancement into the CNS are possible. Total rate of local recurrences is 25 %. The main factors of local and regional recurrences are location (head and neck), size (tumor diameter >2 cm), invasion depth (>4 mm), tumor differentiation, perineural involvement, patient's immune status and previous treatment. Tumors in areas that weren»t subjected to solar radiation and tumors in the areas of pervious irradiation, thermal damage, scarring or chronic ulcers are more prone to recurrences and metastasis. Poorly differentiated and anaplastic SCC is more likely to metastasize compared to well differentiated tumors. Medially located SCC is the area of the face mask and lip is more prone to neural invasion. Multidisciplinary approach with involvement of all specialists in antitumor treatment is necessary for development of treatment tactics.

show abstract

Neoadjuvant intralesional methotrexate in cutaneous squamous cell carcinoma: a comparative cohort study

Abstract: Neoadjuvant MTX-il reduced the presurgical size of cSCC lesions and could simplify their subsequent surgery.

Cited by 34 publications

References 16 publications

Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Patterns of response and acquired resistance to the programmed death‐1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma

Comment on “Intralesional methotrexate for keratoacanthomas: A retrospective cohort study”

Current strategy of squamous cell carcinoma diagnosis and treatment

Contact Info

Product

Resources

About